MAP2K7 and colorectal cancer: Although good tolerability and promising clinical activity, combining an MEK inhibitor with PD-L1 inhibition, were observed in phase I studies in colorectal cancer, these results were not confirmed in a confirmatory phase III clinical trial in colorectal cancer [80].